Axsome Therapeutics Commences Late-Stage Migraine Study


Axsome Therapeutics AXSM has enrolled the first patient in the EMERGE trial of its lead candidate AXS-07 for the acute treatment of migraine.

EMERGE study is a Phase 3 trial to assess the efficacy and safety of AXS-07 in the acute treatment of migraine in patients with a prior inadequate response to an oral Calcitonin Gene-Related Peptide (CGRP) inhibitor.

The trial will enrol upto 100 patients experiencing migraine attacks and will be treated with AXS-07 for up to eight weeks.

The two co-primary endpoints will be pain relief and absence of the most bothersome symptom two hours after dosing.

The study is being conducted to further demonstrate the clinical profile of AXS-07 and is not a regulatory requirement.

Migraine is distinguished by recurrent attacks of pulsating, often severe and disabling head pain associated with nausea, and sensitivity to light and or sound.

Axsome Therapeutics is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options.

Price Action : Axsome shares are trading around 1 percent down at $62.98 on Thursday during pre-market session.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechHealth CareGeneralPatient Enrollment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!